[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600753":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":33,"responsibleParty":50,"collaborators":54,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":18,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":18,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":35,"whyStopped":18,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Chinese PLA General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Assigned Interventions","ACTIVE_COMPARATOR","1. Decitabine: 20 mg\u002Fm²\u002Fday, administered from Day -15 to Day -10.\n2. Ruxolitinib(with Voriconazole):\n\n   * 10 mg twice daily (bid), Day -15 to Day -5\n   * 5 mg twice daily (bid), Day -4 to Day -3\n   * 5 mg once daily (Qd), Day -2\n3. Busulfan (Bu): 0.8 mg\u002Fkg every 6 hours (Q6h), Day -8 to Day -6.\n4. Carmustine (BCNU): 250 mg every 8 hours (Q8h), Day -3.\n5. Cytarabine (Ara-C):\n\n   * 4 g\u002Fm²\u002Fday, Day -10 to Day -9 (for unrelated or haploidentical donors)\n   * 4 g\u002Fm²\u002Fday, Day -9 only (for matched sibling donors)\n6. Cyclophosphamide (CTX): 50 mg\u002Fkg\u002Fday, Day -5 to Day -4. or Fludarabine 30mg\u002Fm2\u002Fday, iv, Day -6 to Day -2;\n7. Antithymocyte Globulin (ATG):\n\n   * 10 mg\u002Fkg\u002Fday, Day -5 to Day -2 (for unrelated or haploidentical donors)\n   * 5 mg\u002Fkg\u002Fday, Day -5 to Day -2 (for matched sibling donors)",[13],"Combination Product: Ruxolitinib, Decitabine",{"label":15,"type":16,"description":17,"interventionNames":18},"The control group","NO_INTERVENTION","1. Busulfan (Bu): 0.8 mg\u002Fkg every 6 hours (Q6h), Day -8 to Day -6.\n2. Carmustine (BCNU): 250 mg every 8 hours (Q8h), Day -3.\n3. Cytarabine (Ara-C):\n\n   * 4 g\u002Fm²\u002Fday, Day -10 to Day -9 (for unrelated or haploidentical donors)\n   * 4 g\u002Fm²\u002Fday, Day -9 only (for matched sibling donors)\n4. Cyclophosphamide (CTX): 50 mg\u002Fkg\u002Fday, Day -5 to Day -4. or Fludarabine 30mg\u002Fm2\u002Fday, iv, Day -6 to Day -2;\n5. Antithymocyte Globulin (ATG):\n\n   * 10 mg\u002Fkg\u002Fday, Day -5 to Day -2 (for unrelated or haploidentical donors)\n   * 5 mg\u002Fkg\u002Fday, Day -5 to Day -2 (for matched sibling donors)",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"COMBINATION_PRODUCT","Ruxolitinib, Decitabine","1. Decitabine: 20 mg\u002Fm²\u002Fday, administered from Day -15 to Day -10.\n2. Ruxolitinib:\n\n   * 10 mg twice daily (bid), Day -15 to Day -5\n   * 5 mg twice daily (bid), Day -4 to Day -3\n   * 5 mg once daily (Qd), Day -2",[9],[26,31],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Li-ping Dou, Dr.","CONTACT","86-10-66937079","lipingruirui@163.com",{"name":32,"role":28,"phone":29,"phoneExt":18,"email":30},"Dai-hong Liu, Dr.",[34],{"facility":5,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Beijing","Beijing Municipality","100853","China","CN",{"type":42,"coordinates":43},"Point",[44,45],116.39723,39.9075,{"lat":45,"lon":44},[48],{"name":32,"role":28,"phone":18,"phoneExt":29,"email":49},"daihongrm@163.com",{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Daihong Liu","Dr.",[55,57],{"name":56,"class":6},"The First Affiliated Hospital of Zhengzhou University",{"name":58,"class":6},"Peking University People's Hospital","100600753","phase-4-ruxolitinib-decitabine-intensified-conditioning-regimen-for-aml-a-randomized-trial-100600753",false,"NCT07101588","Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","Ruxolitinib and Decitabine-Enhanced Conditioning Versus Modified Bu\u002FCy or BuF Conditioning for the Impact on Relapse of Acute Myeloid Leukemia in First Complete Remission (CR1)After Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter, Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* 1\\) Acute myeloid leukemia with indications for allogeneic hematopoietic stem cell transplantation, CR1 2) Have HLA-matched sibling donors or haploidentical donors or ≥8\u002F10 HLA-matched unrelated donors 3) The patients' ages range from 12 to 64 years old 4) Liver function: ALT and AST≤2.5 times the upper limit of normal values, bilirubin ≤2 times the upper limit of normal values 5) Renal function: Creatinine ≤ the upper limit of the normal value 6) There are no uncontrollable infections or serious mental and psychological disorders 7) Sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Patients with acute promyelocytic leukemia (M3) 2. One of the donor and recipient is pregnant 3. Suffering from mental illness or other conditions that prevent one from following the plan.","ALL","14 Years","75 Years",{"count":70,"type":71},200,"ESTIMATED","INTERVENTIONAL",[74],"PHASE4","This study aims to determine whether the recurrence rate of high-risk acute myeloid leukemia CR1 patients who received allogeneic hematopoietic stem cell transplantation with the Ruxolitinib, Decitabine combined with Bu\u002FCy or BuF intensive pretreatment regimen is reduced compared with the traditional Bu\u002FCy or BuFpretreatment regimen.",[77],"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)",[79],"HSCT","2026-03-18",{"date":82,"type":83},"2026-03-20","ACTUAL",{"date":85,"type":83},"2025-01-01",{"date":87,"type":71},"2028-12-30",{"name":5,"class":6},1]